A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

NCT00827034 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease
Huntington's Disease

Interventions

DRUG: Warfarin
DRUG: Dimebon
DRUG: Warfarin

Sponsor

Pfizer

Collaborators

[object Object]